Back to research

Research paper

Landau-Kleffner syndrome and CSWS syndrome: Treatment with intravenous immunoglobulins

Early observational evidence that IVIG produces meaningful cognitive and EEG improvement in LKS and CSWS, particularly when recurrent viral illnesses seem to exacerbate the condition. Foundational citation for the immune-mediated model of DEE-SWAS.

Indexed context

Arts WFM, Aarsen FK, Scheltens-de Boer M, Catsman-Berrevoets CE

iviglandau-kleffner-syndromecswsdee-swasimmunomodulation

Markdown path

content/research/papers/2009-arts-ivig-landau-kleffner-csws.md

Findings

Early observational evidence that IVIG produces meaningful cognitive and EEG improvement in LKS and CSWS, particularly when recurrent viral illnesses seem to exacerbate the condition. Foundational citation for the immune-mediated model of DEE-SWAS.

Why it may matter for Levi

Historical anchor supporting IVIG as a contingent steroid-sparing option if Levi relapses off steroids and a humoral/immune driver remains plausible. Complements the 2023 Saudi multicenter IVIG study already in the corpus. Belongs on the contingent-immunomodulation tier, not first-line.

Paper text

Arts et al. (2009) — LKS and CSWS: Treatment with intravenous immunoglobulins

Source

Why this paper is in the corpus

Early observational evidence that intravenous immunoglobulin (IVIG) produces meaningful cognitive and EEG improvement in Landau-Kleffner syndrome (LKS) and CSWS, particularly when recurrent viral illnesses seem to exacerbate the condition. Foundational citation for the immune-mediated model of DEE-SWAS and one of the older references supporting IVIG as a steroid-sparing option.

Key findings

  • Case series of children with LKS and CSWS treated with IVIG.
  • A meaningful subset showed clinically significant improvement in language, cognition, and EEG activity.
  • Authors argued for an immune-mediated contribution to LKS / CSWS pathogenesis given IVIG responsiveness, especially in children with recurrent infectious exacerbations.

Levi-relevant takeaways

  • Historical anchor for IVIG as a steroid-sparing or steroid-complementary option in DEE-SWAS, complementing the more recent Saudi multicenter 2023 study already in the corpus (2023-ivig-saudi-multicenter-eses.md).
  • Supports IVIG as a contingent treatment option if Levi relapses off steroids and a humoral/immune-mediated driver remains plausible. The April 2026 Th1/Th17-weighted cytokine signature keeps immunomodulation relevant even after the initial steroid pulse response.
  • Note that IVIG is an option worth discussing with Levi's epileptologist but is not a standard first-line DEE-SWAS treatment; it belongs on the contingent-immunomodulation tier.

Citation note

Referenced as [15] in the 2026-04-21 user-supplied comprehensive DEE-SWAS / ESES / CSWS research report.